Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jth.14817 http://scihub22266oqcxt.onion/10.1111/jth.14817 32220112!9906401!32220112     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 253.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 253.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Thromb+Haemost 2020 ; 18 (5): 1094-1099 Nephropedia Template TP {{tp|p=32220112|t=2020. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy |pdf=|usr=}}{{32220112}} gab.com Text Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy JO: J Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32220112 #FOAvip BACKGROUND: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, and the application of heparin in COVID-19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated. METHODS: Coagulation results, medications, and outcomes of consecutive patients being classified as having severe COVID-19 in Tongji hospital were retrospectively analyzed. The 28-day mortality between heparin users and nonusers were compared, as was a different risk of coagulopathy, which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result. RESULTS: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin) for 7 days or longer. D-dimer, prothrombin time, and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference in 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P = .910). But the 28-day mortality of heparin users was lower than nonusers in patients with SIC score >/=4 (40.0% vs 64.2%, P = .029), or D-dimer >6-fold of upper limit of normal (32.8% vs 52.4%, P = .017). CONCLUSIONS: Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer. Twit Text FOAVip Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy ????J Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32220112 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32220112 #FOAvip English Wikipedia <ref>{{Cite pmid|32220112}}</ref> Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy #MMPMID32220112 Tang N; Bai H; Chen X; Gong J; Li D; Sun Z J Thromb Haemost 2020[May]; 18 (5): 1094-1099 PMID32220112show ga BACKGROUND: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, and the application of heparin in COVID-19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated. METHODS: Coagulation results, medications, and outcomes of consecutive patients being classified as having severe COVID-19 in Tongji hospital were retrospectively analyzed. The 28-day mortality between heparin users and nonusers were compared, as was a different risk of coagulopathy, which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result. RESULTS: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin) for 7 days or longer. D-dimer, prothrombin time, and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference in 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P = .910). But the 28-day mortality of heparin users was lower than nonusers in patients with SIC score >/=4 (40.0% vs 64.2%, P = .029), or D-dimer >6-fold of upper limit of normal (32.8% vs 52.4%, P = .017). CONCLUSIONS: Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer. |*Betacoronavirus[MESH] |*Coronavirus Infections/complications/drug therapy/mortality[MESH] |*Disseminated Intravascular Coagulation/drug therapy/etiology[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/complications/drug therapy/mortality[MESH] |Age Factors[MESH] |Aged[MESH] |Anticoagulants/administration & dosage/*therapeutic use[MESH] |Biomarkers/*blood[MESH] |Blood Coagulation Tests[MESH] |COVID-19[MESH] |Female[MESH] |Fibrin Fibrinogen Degradation Products[MESH] |Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Platelet Count[MESH] |Prognosis[MESH] |Prothrombin Time[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH]Anticoagulant treatment is associated with decreased mortality in seve(epmc).pdf DeepDyve Pubget Overpricing